Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 16,107 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Withdrawn Early Phase 1 Interventional

Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

NCT05957042
View directory record Official record
Conditions
Breast Cancer, Contrast Enhanced Ultrasound
Interventions
Lumason
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 27, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

NCT03787303
View directory record Official record
Conditions
Metastatic Breast Cancer, Thyroid Dysfunction
Interventions
Triiodothyronine (T3)
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 105 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 1 Interventional Results available

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

NCT01271803
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Cobimetinib, vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

NCT01071954
View directory record Official record
Conditions
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Interventions
Romiplostim
Biological
Lead sponsor
Amgen
Industry
Eligibility
1 Year and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
24
States / cities
Orange, California • San Diego, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 27, 2026, 6:03 AM EDT
Terminated No phase listed Observational

Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy

NCT00925405
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast MRI, Mammogram
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Taxotere

NCT00206505
View directory record Official record
Conditions
Breast Cancer
Interventions
Taxotere
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 27, 2026, 6:03 AM EDT
Recruiting No phase listed Observational

Study in Patients With Breast Cancer Leptomeningeal Metastasis

NCT06638294
View directory record Official record
Conditions
Leptomeningeal Metastasis of Breast Cancer
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Weeks and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 27, 2026, 6:03 AM EDT
Completed No phase listed Observational

Anastrozole and Letrozole

NCT00762294
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
UConn Health
Other
Eligibility
40 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT

NCT02643966
View directory record Official record
Conditions
Breast Cancer
Interventions
Whole breast ultrasound
Device
Lead sponsor
Wendie Berg
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
6,266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 27, 2026, 6:03 AM EDT
Completed No phase listed Observational

Sun Exposure and Melanoma in Agricultural Workers

NCT00901966
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Physical Activity Platform to Improve Bone Health in Cancer Survivors

NCT03651037
View directory record Official record
Conditions
Breast Cancer, Physical Activity, Bone Health
Interventions
Thrivors+BH
Behavioral
Lead sponsor
Thrivors Inc
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

NCT01153672
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
vorinostat, laboratory biomarker analysis, biopsy, F-18 16 alpha-fluoroestradiol, positron emission tomography, anastrozole, letrozole, exemestane, gene expression analysis
Drug · Other · Procedure + 2 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

NCT04091672
View directory record Official record
Conditions
Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin, Surgical Wound, Skin Cancer, Cellulitis, Infection, Necrotizing Fasciitis, Gun Shot Wound
Interventions
Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
Procedure · Device
Lead sponsor
Avita Medical
Industry
Eligibility
5 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT01975831
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

NCT00393939
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sunitinib malate, Taxotere
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Berkely, California • Shreveport, Louisiana • Beaumont, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Early Phase 1 Interventional

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

NCT04581382
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Pembrolizumab, Radiation Therapy, Therapeutic Exchange Plasma, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

NCT05244980
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

NCT02933879
View directory record Official record
Conditions
Onychomycosis
Interventions
NVXT topical, Placebo (Vehicle) Topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 2 Interventional

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

NCT03482479
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
Interventions
Naltrexone Hydrochloride, Placebo Comparator
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 3 Interventional

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

NCT04032080
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Drug 1: LY3023414; Drug 2: Prexasertib
Combination Product
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

NCT01265927
View directory record Official record
Conditions
Breast Neoplasms
Interventions
GRN163L in combination with trastuzumab
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 27, 2026, 6:03 AM EDT
Withdrawn Phase 2 Interventional

Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels

NCT00851370
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Omalizumab (Xolair), Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

NCT03004183
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
Interventions
ADV/HSV-tk, Valacyclovir, SBRT, Pembrolizumab
Biological · Drug · Radiation
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 27, 2026, 6:03 AM EDT